CMMB

Chemomab Therapeutics Ltd.

Price

$2.69

return (12m)

1.51%

p/e

-184.61

p/bv

198.07

DIVIDEND YIELD

0.00%

CMMB price

Chemomab Therapeutics

If you had invested

exposure

years ago

ago, you would now have *

ago, you would now have:

*This calculation reflects price variation only.

Return on Investment CMMB

1 month

3 months

1 year

2 years

5 years

10 years

return

1 month

26.29%

3 months

76.97%

1 year

1.51%

2 years

-59.97%

5 years

-94.55%

10 years

0.00%

Profitability Comparator

If you had invested

years ago

ago, you would now have:

Fundamentals CMMB

Valuation

P/E

-184.61

Sector -3.50

Industry -3.50

P/BV

198.07

Sector 2.02

Industry 2.02

P/Revenue (PSR)

Sector 2.01

Industry 2.01

EV/EBITDA

Sector -214.99

Industry -214.99

EV/EBIT

Sector -47.59

Industry -47.59

P/EBITDA

-217.61

Sector -21.41

Industry -21.41

P/EBIT

-217.61

Sector -28.65

Industry -28.65

P/Total Assets

168.02

Sector 1.19

Industry 1.19

P/Net Current Assets

204.69

Sector -11.97

Industry -11.97

P/Working Capital

204.69

Sector -167.95

Industry -167.95

EPS

-0.01

Sector -1.81

Industry -1.81

BVPS

0.01

Sector 2.06

Industry 2.06

Efficiency

Gross Margin

0.00%

Sector 41.30%

Industry 41.30%

EBITDA Margin

Sector -17,117.21%

Industry -17,117.21%

EBIT Margin

Sector -4,185,659.35%

Industry -4,185,659.35%

Operating Margin

0.00%

Sector -35.21%

Industry -35.21%

Net Profit Margins

0.00%

Sector -35.91%

Industry -35.91%

Asset Turnover

Sector 0.02

Industry 0.02

Profitability

ROE

-107.29%

Sector -56.04%

Industry -56.04%

ROA

-91.01%

Sector -60.31%

Industry -60.31%

ROIC

-295.55%

Sector -2,335.95%

Industry -2,335.95%

Dividends

Dividend yield

0.00%

Sector -

Industry -

Payout

Sector -

Industry -

Debt

Current Ratio

6.41

Sector 2.89

Industry 2.89

Net Debt / EBITDA

Sector -14,066,680.10

Industry -14,066,680.10

Net Debt / EBIT

Sector -8.06

Industry -8.06

Net Debt / Equity

Sector -33,024.69

Industry -33,024.69

Gross Debt / Equity

Sector -0.85

Industry -0.85

Equity/Assets

0.85

Sector 0.46

Industry 0.46

Liabilities/Assets

0.15

Sector 0.41

Industry 0.41

Growth

5Y Revenue CAGR

0.00%

Sector -

Industry -

5Y Earnings CAGR

-5.67%

Sector -

Industry -

Fundamentals CMMB

DRAG THE FRAME TO SEE MORE DATA

Assets	Price (US$)	Return 12m	DY	P/E	P/BV	ROE	Net Profit Margins
CMMB Chemomab Therapeutics Ltd.	$2.69	2.67%	0.00%	-184.61	198.07	-107.29%	0.00%
JNJ Johnson & Johnson	$269.33	55.44%	1.96%	30.82	7.63	24.76%	21.48%
PFE Pfizer Inc.	$27.49	22.33%	6.26%	35.85	1.83	5.11%	6.86%
ABBV AbbVie Inc.	$263.93	23.34%	2.59%	73.99	-78.76	-106.44%	9.81%
NVO Novo Nordisk A/S	$43.19	-26.70%	4.29%	10.56	5.61	53.11%	35.32%
MRK Merck & Co. Inc.	$146.11	87.14%	2.31%	113.21	8.55	7.55%	4.76%
AZN AstraZeneca PLC	$166.35	9.78%	1.94%	19.88	5.12	25.77%	16.95%
BMY Bristol-Myers Squibb Company	$62.71	43.77%	4.04%	13.67	5.68	41.55%	18.85%
ZTS Zoetis Inc.	$72.66	-49.60%	2.88%	11.47	9.64	84.02%	27.77%
AMGN Amgen Inc.	$383.04	43.28%	2.60%	23.66	17.70	74.80%	22.95%
REGN Regeneron Pharmaceuticals Inc.	$784.44	31.54%	0.47%	18.63	2.54	13.65%	27.86%
HALO Halozyme Therapeutics Inc.	$111.35	46.87%	0.00%	31.57	90.97	288.13%	24.86%
MCK McKesson Corporation	$874.67	27.00%	0.38%	19.57	-26.84	-137.16%	1.29%
VRTX Vertex Pharmaceuticals Incorporated	$506.08	30.72%	0.00%	29.15	6.34	21.76%	35.00%
CAH Cardinal Health Inc.	$224.45	52.89%	0.91%	30.53	-19.32	-63.29%	0.68%
ARGX argenx SE	$994.44	35.42%	0.00%	2.24	2.63	117.11%	44.68%
HRMY Harmony Biosciences Holdings Inc.	$42.23	31.71%	0.00%	13.50	2.45	18.14%	18.88%

Stock vs Indice Comparison Tool

If you had invested

years ago

ago, you would now have *

ago, you would now have:

*This calculation reflects price variation only.

CMMB Historical Dividends

current DY: 0.00%

5-year average DY: 0.00%

no dividend paid in the period.

ABOUT Chemomab Therapeutics

Chemomab Therapeutics Ltd.

Average Investor10 user rating

4.0 (0 people)

United States

11 years

Founded: 2015

2021

Time since IPO - 5 years

-

Employees

Chemomab Therapeutics Ltd. (United States) is listed on the Nasdaq and has a market capitalization of $1.72 billion, with shareholders equity totaling $8.69 million.

The Company is listed on the [MARKET_NAME]

Over the past 12 months, Chemomab Therapeutics Ltd. reported $- in revenue, generating net income of $-9.32 million.

Key financial metrics include a P/E ratio of -184.61, a price-to-book (P/B) ratio of 198.07, and a trailing twelve-month dividend yield of 0.00%.

The company trades under the ticker CMMB.

Market cap

$1.72 billion

Net worth

$8.69 million

$8,685,000.00

Assets

$10.24 million

$10,238,000.00

Total Shares Outstanding

639.48 million

639,483,000

Average Daily Trading Volume

$98.66 Thousand

$98,662.00

Sector

Health Care

Industry

Biotechnology

CMMB

CMMB revenue and profits

Financial Results CMMB

DRAG THE FRAME TO SEE MORE DATA

CMMB cash flow

DRAG THE FRAME TO SEE MORE DATA

Discover more assets

BFRA - Biofrontera

$- -0,00% (12M)

P/E

0.00

0.00%

ROE

-893.55%

P/BV

0.00

MCK - McKesson

$874.67 25,76% (12M)

P/E

19.57

0.38%

ROE

-137.16%

P/BV

-26.84

CAH - Cardinal Health

$224.45 51,61% (12M)

P/E

30.53

0.91%

ROE

-63.29%

P/BV

-19.32

JNJ - Johnson & Johnson

$269.33 56,33% (12M)

P/E

30.82

1.96%

ROE

24.76%

P/BV

7.63

ABBV - AbbVie

$263.93 22,42% (12M)

P/E

73.99

2.59%

ROE

-106.44%

P/BV

-78.76

MRK - Merck & Co.

$146.11 85,19% (12M)

P/E

113.21

2.31%

ROE

7.55%

P/BV

8.55

AZN - AstraZeneca

$166.35 9,17% (12M)

P/E

19.88

1.94%

ROE

25.77%

P/BV

5.12

PFE - Pfizer

$27.49 22,43% (12M)

P/E

35.85

6.26%

ROE

5.11%

P/BV

1.83

BFRA - Biofrontera

$- -0,00% (12 M)

P/L

0.00

0.00%

ROE

-893.55%

P/VP

0.00

MCK - McKesson

$874.67 25,76% (12 M)

P/L

19.57

0.38%

ROE

-137.16%

P/VP

-26.84

CAH - Cardinal Health

$224.45 51,61% (12 M)

P/L

30.53

0.91%

ROE

-63.29%

P/VP

-19.32

JNJ - Johnson & Johnson

$269.33 56,33% (12 M)

P/L

30.82

1.96%

ROE

24.76%

P/VP

7.63

ABBV - AbbVie

$263.93 22,42% (12 M)

P/L

73.99

2.59%

ROE

-106.44%

P/VP

-78.76

MRK - Merck & Co.

$146.11 85,19% (12 M)

P/L

113.21

2.31%

ROE

7.55%

P/VP

8.55

AZN - AstraZeneca

$166.35 9,17% (12 M)

P/L

19.88

1.94%

ROE

25.77%

P/VP

5.12

PFE - Pfizer

$27.49 22,43% (12 M)

P/L

35.85

6.26%

ROE

5.11%

P/VP

1.83

Frequently Asked Questions

What is the price of Chemomab Therapeutics (CMMB) today?

A cotação de Chemomab Therapeutics (CMMB) hoje está em US$ 2.69, com uma variação de 1.51% em relação ao último ano. A cotação de Chemomab Therapeutics (CMMB) iniciou o ano negociando na casa dos US$ 1.65 e hoje está em US$ 2.69. Acompanhe o gráfico de cotação em tempo real, a cotação histórica de Chemomab Therapeutics (CMMB) e dados de ações do Ibovespa e mercados internacionais.

Quando Chemomab Therapeutics (CMMB) paga dividendos?

Chemomab Therapeutics (CMMB) não distribuiu dividendos no último ano.

Is Chemomab Therapeutics (CMMB) a good investment?

Atualmente, Chemomab Therapeutics (CMMB) está cotada a US$ 2.69, com um P/L de -184.61, representando um desvio de -4,691% em relação ao seu P/L médio histórico. No último ano, a ação apresentou uma variação de 1.51 em sua cotação e distribuiu US$ 0.00 em dividendos, resultando em um Dividend Yield de 0.00%. O retorno total do acionista foi de 1.51%.

Investors should keep in mind that past performance does not guarantee future results. This information is provided for educational purposes only and should not be considered investment advice.

How can I buy Chemomab Therapeutics (CMMB) stock?

Investir em ações de Chemomab Therapeutics (CMMB) pode ser feito de duas formas: comprando a stock uma empresa estrangeira e é atrelado ao dólar.

How much would 100 shares of Chemomab Therapeutics (CMMB) yield today?

A rentabilidade de Chemomab Therapeutics (CMMB) foi de 26.29% no último mês, 1.51% no último ano e -94.55% nos últimos 5 anos (já considerando valorização e dividendos).

Nos últimos 12 meses, a empresa pagou um total de US$ 0.00 em dividendos, um Dividend Yield de 0.00%.

Se você quisesse comprar 100 ações de Chemomab Therapeutics (CMMB) hoje, o investimento total seria de US$ 269.00, com base na cotação atual de US$ 2.69.

Based on historical performance, the investment would have grown to approximately:

Em 1 ano: US$ 273.06
Em 5 anos: US$ 14.66
Em 10 anos: US$ 269.00

Past performance does not guarantee future results. This content is for informational purposes only and should not be considered investment advice.

CMMB

Chemomab Therapeutics Ltd.

Price

return (12m)

p/e

p/bv

DIVIDEND YIELD

Return on Investment CMMB

Valuation

Efficiency

Profitability

Dividends

Debt

Growth

COMPARING CMMB WITH OTHER STOCK

current DY: 0.00%

5-year average DY: 0.00%

ABOUT Chemomab Therapeutics

Chemomab Therapeutics Ltd.

United States

11 years

2021

-

PROFIT X PRICE CMMB

Financial Results CMMB

CMMB cash flow

Asset, Revenue and Profit Growth - CMMB

CMMB balance sheet

BFRA - Biofrontera

MCK - McKesson

CAH - Cardinal Health

JNJ - Johnson & Johnson

ABBV - AbbVie

MRK - Merck & Co.

AZN - AstraZeneca

PFE - Pfizer

BFRA - Biofrontera

MCK - McKesson

CAH - Cardinal Health

JNJ - Johnson & Johnson

ABBV - AbbVie

MRK - Merck & Co.

AZN - AstraZeneca

PFE - Pfizer

Frequently Asked Questions